The National Health Surveillance Agency (Anvisa) is analyzing studies for the production of an aviary flu vaccine in Brazil. The Butantan Institute, responsible for the development of the immunizer, awaits the approval of the regulatory agency to proceed with the research.
The Brazilian vaccine project against avian flu is currently in the transition from phase 1 to phase 2 of clinical studies. Anvisa’s approval is crucial for the Butantan Institute to continue the immunizer development process.
Potential global impact
If the project is successful, Brazil could become an important producer of the avian flu vaccine, contributing to the prevention of possible future epidemics on a global scale.
Importantly, despite concern for the disease, cases of infection in humans have been relatively low. Between 2003 and 2024, 954 cases of people infected with avian flu were recorded in 24 countries, representing an average of less than 100 cases a year worldwide.
Experts emphasize that the Brazilian health system is internationally recognized for its efficiency and serves as a reference for many countries. The recent detection of an avian flu case in a wild bird in Rio Grande do Sul should not be a panic, but an alert to the importance of constant surveillance and the development of preventive measures such as the vaccine under study.
Avian flu: what it is, what the symptoms and how the treatment is done
This content was originally published in the first vaccine against Avian flu is in studies in Brazil on the website CNN Brazil.
Source: CNN Brasil
I am an experienced journalist and writer with a career in the news industry. My focus is on covering Top News stories for World Stock Market, where I provide comprehensive analysis and commentary on markets around the world. I have expertise in writing both long-form articles and shorter pieces that deliver timely, relevant updates to readers.
